Constanta Timcheva

1.3k total citations
23 papers, 474 citations indexed

About

Constanta Timcheva is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Constanta Timcheva has authored 23 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 6 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Constanta Timcheva's work include BRCA gene mutations in cancer (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Constanta Timcheva is often cited by papers focused on BRCA gene mutations in cancer (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Constanta Timcheva collaborates with scholars based in United Kingdom, Bulgaria and Hungary. Constanta Timcheva's co-authors include Tudor–Eliade Ciuleanu, G. Bodoky, G. Pover, Niall C. Tebbutt, David R. Spigel, Phillip J. Stella, Ljiljana Stamatović, Piotr Zaborek, Т. Yu. Semiglazova and Jozef Mardiak and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Constanta Timcheva

22 papers receiving 463 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Constanta Timcheva United Kingdom	9	384	127	124	94	49	23	474
Shristi Bhattarai United States	14	239 0.6×	114 0.9×	162 1.3×	72 0.8×	57 1.2×	28	442
Marco Brugia Italy	12	218 0.6×	117 0.9×	100 0.8×	128 1.4×	27 0.6×	31	354
Shan Zheng China	13	271 0.7×	106 0.8×	133 1.1×	103 1.1×	33 0.7×	41	482
Séverine Sarp Switzerland	9	196 0.5×	119 0.9×	109 0.9×	76 0.8×	28 0.6×	18	398
Bryan A. Faller United States	11	325 0.8×	196 1.5×	83 0.7×	179 1.9×	44 0.9×	32	532
Elsa Curtit France	11	216 0.6×	76 0.6×	115 0.9×	106 1.1×	38 0.8×	45	441
Claudia Arce-Salinas Mexico	11	241 0.6×	138 1.1×	177 1.4×	80 0.9×	86 1.8×	25	448
Rebecca Shatsky United States	9	254 0.7×	81 0.6×	107 0.9×	97 1.0×	30 0.6×	38	356
Valerie Bée United States	9	297 0.8×	145 1.1×	145 1.2×	71 0.8×	30 0.6×	13	475
N. Afonso Portugal	13	244 0.6×	106 0.8×	100 0.8×	86 0.9×	29 0.6×	28	495

Countries citing papers authored by Constanta Timcheva

Since Specialization

Citations

This map shows the geographic impact of Constanta Timcheva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constanta Timcheva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constanta Timcheva more than expected).

Fields of papers citing papers by Constanta Timcheva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constanta Timcheva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constanta Timcheva. The network helps show where Constanta Timcheva may publish in the future.

Co-authorship network of co-authors of Constanta Timcheva

This figure shows the co-authorship network connecting the top 25 collaborators of Constanta Timcheva. A scholar is included among the top collaborators of Constanta Timcheva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constanta Timcheva. Constanta Timcheva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pignata, Sandro, Amit M. Oza, Geoff Hall, et al.. (2025). Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status. British Journal of Cancer. 132(8). 725–732.

Gelmon, Karen A., PA Fasching, Suzette Delaloge, et al.. (2023). 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial. ESMO Open. 8(1). 101392–101392. 1 indexed citations

Pignata, Sandro, Amit M. Oza, Geoff Hall, et al.. (2023). Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. Gynecologic Oncology. 172. 121–129. 12 indexed citations

Borštnar, Simona, Markéta Palácová, Aleksandra Łacko, et al.. (2022). Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial. Radiology and Oncology. 56(2). 238–247. 2 indexed citations

Pignata, Sandro, Amit M. Oza, Geoff Hall, et al.. (2021). ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status. Gynecologic Oncology. 162. S29–S29. 4 indexed citations

Twelves, Chris, Rupert Bartsch, Noa Ben-Baruch, et al.. (2021). The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. Clinical Breast Cancer. 22(3). 223–234. 7 indexed citations

Conev, Nikolay, et al.. (2020). Sarcopenia as a negative predictive marker for treatment with pembrolizumab as a second line in patients with metastatic non-small cell lung cancer.. Journal of Clinical Oncology. 38(15_suppl). e21541–e21541. 1 indexed citations

Petrova, Mila, Nikolay Conev, Krassimir Koynov, et al.. (2020). Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer. BioScience Trends. 14(1). 48–55. 47 indexed citations

Petrova, Mila, et al.. (2020). Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. Clinical & Experimental Immunology. 202(3). 353–362. 29 indexed citations

10.

Twelves, Chris, Alan Anthoney, Matthew Guo, et al.. (2019). A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer. 120(6). 579–586. 2 indexed citations

11.

Mok, Tony, Peter Schmid, Gilberto de Castro, et al.. (2017). P2.06-022 First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study. Journal of Thoracic Oncology. 12(1). S1084–S1084. 5 indexed citations

12.

Gaillard, Stéphanie, Sharad Ghamande, Beatriz Pardo, et al.. (2016). CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 34(15_suppl). TPS5597–TPS5597. 9 indexed citations

13.

Mok, Tony, Peter Schmid, Gilberto de Castro, et al.. (2016). 482TiP Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE. Annals of Oncology. 27(suppl_9). 2 indexed citations

14.

Mok, Tony, Peter Schmid, Osvaldo Rudy Aren, et al.. (2015). 480TiP Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE. Annals of Oncology. 26. ix125–ix125. 2 indexed citations

15.

Jassem, Jacek, Vahit Özmen, J. Eglītis, et al.. (2013). Delays in diagnosis and treatment of breast cancer: a multinational analysis. European Journal of Public Health. 24(5). 761–767. 105 indexed citations

16.

Jassem, Jacek, J. Eglītis, Jozef Mardiak, et al.. (2012). Patient-related factors influencing time between first signs of breast cancer (BC) and appointment for medical visit (AMV): An international survey.. Journal of Clinical Oncology. 30(15_suppl). 9046–9046. 2 indexed citations

17.

Bodoky, G., Constanta Timcheva, David R. Spigel, et al.. (2011). A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Investigational New Drugs. 30(3). 1216–1223. 197 indexed citations

18.

Pirker, Robert, Stephen Brincat, Peter Kasan, et al.. (2010). Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer. 70(1). 7–13. 12 indexed citations

19.

Tomova, Antoaneta, Rupert Bartsch, Thomas Brodowicz, et al.. (2009). Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Research and Treatment. 119(1). 169–176. 14 indexed citations

20.

Timcheva, Constanta, et al.. (1996). Does Verapamil Help Overcome Multidrug Resistance in Tumor Cell Lines and Cancer Patients?. Journal of Chemotherapy. 8(4). 295–299. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact